AAN 2024 | CHIMES: ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing MS

Lilyana Amezcua, MD, FAAN, Keck School of Medicine, University of Southern California, Los Angeles, CA, discusses the Phase IV CHIMES trial (NCT04377555), evaluating ocrelizumab’s efficacy in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS). Over 50% achieved the primary 48-week no evidence of disease activity (NEDA) endpoint, with over 90% avoiding relapse. MRI findings showed 50% with no new/enlarged T2 lesions, improving notably between weeks 24 and 48. In this understudied patient population, ocrelizumab demonstrated efficacy comparable to what has been observed in predominantly white patients in the OPERA I (NCT01247324) and OPERA II (NCT01412333) trials. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.